ABO and Alzheimer disease: These findings suggest that the specific signature of soluble Aβo-induced neurodegeneration on wake/sleep EEG features could be used as an early biomarker of AD, when soluble Aβo accumulation occurs and other pathological, structural, and clinical events related to AD are undetectable.